Skip to main content
. 2015 Oct 13;6(33):34258–34275. doi: 10.18632/oncotarget.5545

Figure 4. Arenobufagin activates the ATM/ATR-Chk1/Chk2 signaling pathway.

Figure 4

HepG2, HepG2/ADM and Hep3B cells treated with arenobufagin for 0, 24, 36 and 48 h. 293 cell extracts were exposed to UV for 4 h. Cells were collected and lysed. The lysates were assayed by Western blotting with the indicated antibodies. The representative pictures from 3 independent experiments are shown.